Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...

Healthcare Associated Infections II: Preventive Measures

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trial.

The Lancet. Child & adolescent health·2026

Same author

The case for evaluation of double mutant heat-labile toxin as an adjuvant to improve oral cholera vaccine immunogenicity.

Frontiers in immunology·2026

Same author

Influenza vaccine effectiveness against influenza-associated hospitalizations and emergency department or urgent care encounters among children and adults - United States, 2024-25 season.

medRxiv : the preprint server for health sciences·2026

Same author

Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults: A Cluster Randomized Crossover Study.

JAMA network open·2026

Same author

SARS-CoV-2 Vaccination Before and During Pregnancy and Prevention of Infant COVID-19 Infection.

Pediatrics·2026

Same author

Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.

MMWR. Morbidity and mortality weekly report·2026

Search research articles

Related Experiment Video

Updated: Dec 21, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into

Roger Baxter¹, Laurie Aukes¹, Stephen I Pelton^2,3

¹Vaccine Study Center, Kaiser Permanente, Oakland, California, USA.

Journal of the Pediatric Infectious Diseases Society

|May 17, 2020

Summary

The 13-valent pneumococcal conjugate vaccine (PCV13) significantly reduced invasive pneumococcal disease (IPD) incidence in all age groups. This vaccine introduction demonstrated both direct protection in children and indirect benefits in adults.

Keywords:

Streptococcus pneumoniae all ages PCV13 invasive pneumococcal disease

More Related Videos

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

Experimental Human Pneumococcal Carriage

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Related Experiment Videos

Last Updated: Dec 21, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

Experimental Human Pneumococcal Carriage

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Area of Science:

Immunology
Vaccinology
Epidemiology

Background:

The 13-valent pneumococcal conjugate vaccine (PCV13) replaced the 7-valent PCV (PCV7) in 2010 for invasive pneumococcal disease (IPD) prevention.
This study analyzes laboratory surveillance data to assess PCV13's impact on IPD rates.

Purpose of the Study:

To evaluate the effectiveness of PCV13 in reducing IPD incidence.
To compare IPD rates before and after PCV13 introduction across different age groups.

Main Methods:

Utilized observational, laboratory-based IPD surveillance data from Kaiser Permanente Northern California (KPNC).
Compared data from May 2008-April 2010 (PCV7 period) with May 2010-April 2018 (post-PCV13 introduction).

Main Results:

Overall IPD incidence decreased from 11.57 to 4.09 per 100,000 in children aged 6 weeks to 6 years.
PCV13-type IPD incidence dropped significantly, while non-PCV13 serotype IPD remained stable.
Across all ages, IPD incidence declined, primarily due to reductions in serotypes 19A and 7F.

Conclusions:

PCV13 introduction led to a further decrease in IPD incidence across all age groups.
Observed reductions suggest both direct vaccination effects in infants and indirect effects in unvaccinated individuals.